LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Ryan B. Corcoran(Massachusetts General Hospital), Robin M.J.M. van Geel(The Netherlands Cancer Institute), Johanna C. Bendell(Dana-Farber Cancer Institute), Peter J. O’Dwyer(University of Pennsylvania), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Y. Liu(Novartis (Switzerland)), Takayuki Yoshino(University of Tsukuba), Chloé E. Atreya(The University of Texas MD Anderson Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Kei Muro(Aichi Cancer Center), Thierry André(Inserm), Bijoyesh Mookerjee(Novartis (United States)), Michel Ducreux(Université Paris-Saclay), Fatima Rangwala(Novartis (United States)), Autumn J. McRee(University of North Carolina at Chapel Hill), James Greger(Novartis (Switzerland)), Ying Wu(Novartis (Switzerland)), Jan H.M. Schellens(Utrecht University), R. Sidhu(Amgen (United States)), Josep Tabernero(Deaconess Hospital)
Cited by 23
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k